Search - tctmd.com

Displaying 221 - 240 of 553

Sort: Relevancy | Date

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

News Daily News

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

November 01, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

Higher Dose vs Added Antihypertensive? Older Patients Face Trade-offs

News Daily News

Higher Dose vs Added Antihypertensive? Older Patients Face Trade-offs

Yael L. Maxwell

October 07, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

News Daily News

High Burden of CAD in Chest Pain Patients With ‘Normal’ Troponin

Michael O'Riordan

September 27, 2021

Heterozygous FH Diagnosed Late, Remains Undertreated

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

News Daily News

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

September 08, 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

August 31, 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

News Conference News ESC 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

August 30, 2021

News Conference News ESC 2021

SMART-MI: Implant IDs Large Burden of Arrhythmic Events Post-MI

Michael O'Riordan

August 27, 2021

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

News Daily News

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

August 20, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.